<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1392</article-id><article-id pub-id-type="doi">10.17650/17269776-2021-17-2-46-52</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железы</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The first experience of transperineal prostate biopsy without antibiotic prophylaxis</article-title><trans-title-group xml:lang="ru"><trans-title>Первый опыт выполнения трансперинеальной биопсии предстательной железы без антибиотикопрофилактики</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0469-7007</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernysheva</surname><given-names>D. Yu.</given-names></name><name xml:lang="ru"><surname>Чернышева</surname><given-names>Д. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dar'ya Yu. Chernysheva.</p><p>46 Chugunnaya St., Saint-Petersburg 194044.</p></bio><bio xml:lang="ru"><p>Чернышева Дарья Юрьевна.</p><p>194044 Санкт-Петербург, ул. Чугунная, 46.</p><p>SPIN‐код: 3039-8004</p></bio><email>daria.chern@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2767-7153</contrib-id><name-alternatives><name xml:lang="en"><surname>Popov</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Попов</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>46 Chugunnaya St., Saint-Petersburg 194044; 6 Akademika Lebedeva St., Saint-Petersburg 194044.</p></bio><bio xml:lang="ru"><p>Попов Сергей Валерьевич - главный врач СПбГБУЗ «Клиническая больница Святителя Луки», профессор кафедры урологии ВМедА им. С.М. Кирова, доцент кафедры урологии СПбГУ.</p><p>194044 Санкт-Петербург, ул. Чугунная, 46; 194044 Санкт-Петербург, ул. Академика Лебедева, 6.</p><p>SPIN‐код: 3830-9539</p></bio><email>doc.popov@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5566-9789</contrib-id><name-alternatives><name xml:lang="en"><surname>Orlov</surname><given-names>I. N.</given-names></name><name xml:lang="ru"><surname>Орлов</surname><given-names>И. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>46 Chugunnaya St., Saint-Petersburg 194044; 41 Kirochnaya St., Saint-Petersburg 191015.</p></bio><bio xml:lang="ru"><p>Орлов Игорь Николаевич - заведующий отделением городского центра эндоурологии и новых технологий, СПбГБУЗ «Клиническая больница Святителя Луки»; ассистент кафедры урологии СЗГМУ им. И.И. Мечникова.</p><p>194044 Санкт-Петербург, ул. Чугунная, 46; 191015 Санкт-Петербург, ул. Кирочная, 41.</p><p>SPIN‐код: 2116-4127</p></bio><email>doc.orlov@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6169-2539</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsoy</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Цой</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>46 Chugunnaya St., Saint-Petersburg 194044.</p></bio><bio xml:lang="ru"><p>Цой Алексей Валерьевич.</p><p>194044 Санкт-Петербург, ул. Чугунная, 46.</p><p>SPIN‐код: 4253-9083</p></bio><email>alekseytsoy93@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4113-0525</contrib-id><name-alternatives><name xml:lang="en"><surname>Neradovskiy</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Нерадовский</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>46 Chugunnaya St., Saint-Petersburg 194044.</p></bio><bio xml:lang="ru"><p>Нерадовский Вячеслав Александрович.</p><p>194044 Санкт-Петербург, ул. Чугунная, 46.</p><p>SPIN‐код: 9941-1434</p></bio><email>neraddocuro@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">St. Luka's Clinical Hospital</institution></aff><aff><institution xml:lang="ru">Клиническая больница Святителя Луки</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Department of Urology, S.M. Kirov Military Medical Academy, Ministry of Defense of Russia</institution></aff><aff><institution xml:lang="ru">кафедра урологии Военно-медицинской академии им. С.М. Кирова Минобороны России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Department of Urology, I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">кафедра урологии Северо-Западного государственного медицинского университета им. И.И. Мечникова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-07-25" publication-format="electronic"><day>25</day><month>07</month><year>2021</year></pub-date><volume>17</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>46</fpage><lpage>52</lpage><history><date date-type="received" iso-8601-date="2021-01-13"><day>13</day><month>01</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-03-04"><day>04</day><month>03</month><year>2021</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1392">https://oncourology.abvpress.ru/oncur/article/view/1392</self-uri><abstract xml:lang="en"><p><bold>Objective</bold>: to study the safety of omitting the antibiotic prophylaxis before transperineal prostate biopsy.</p><p><bold>Materials and methods</bold>. The prospective randomized study included data, obtained during the diagnostical process of 85 patients, who underwent transperineal prostate biopsy in 2020. In the control group (<italic>n</italic> = 50) patients received 1 g Ceftriaxone IV 1 h before the biopsy. In the study group (<italic>n</italic> = 35) biopsy was performed without previous antibacterial prophylaxis. Age median was 63.2 (52-75) years.</p><p><bold>Results</bold>. No significant differences in the infection complications rate (UTI, soft tissues infections, prostatitis, fever, sepsis) were obtained between the groups. No patient developed UTI, prostatitis or sepsis, confirmed with urine culture.</p><p><bold>Conclusion</bold>. Performing transperineal prostate biopsy without antibiotic prophylaxis seems to be a safe alternative to common prophylaxis regiments, dedicated to infection complications prevention after prostate biopsy.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования</bold> - оценить безопасность проведения трансперинеальной биопсии предстательной железы без антибиотикопрофилактики.</p><p><bold>Материалы и методы</bold>. В проспективное рандомизированное исследование включены данные, полученные в ходе диагностического обследования 85 пациентов, которым с января по декабрь 2020 г. была выполнена промежностная биопсия предстательной железы. Пациенты контрольной группы (<italic>n</italic> = 50) за 1 ч до биопсии получали 1 г цефтриаксона внутривенно, а пациентам исследуемой группы (<italic>n</italic> = 35) антибиотикопрофилактика до манипуляции не проводилась. Медиана возраста пациентов составила 63,2 (52-75) года.</p><p><bold>Результаты</bold>. Достоверных различий в частоте возникновения инфекционных осложнений (инфекция мочевых путей, инфекция мягких тканей промежности, простатит, лихорадка, сепсис) между группами не получено. Ни у одного пациента не зафиксировано мочевых инфекций и простатита, подтвержденных данными культурального исследования, а также сепсиса.</p><p><bold>Заключение</bold>. Проведение трансперинеальной биопсии предстательной железы без использования антибиотикопрофилактики представляется безопасной альтернативой привычной трансректальной биопсии с антибактериальной профилактикой инфекционных осложнений, возникающих после данной процедуры.</p></trans-abstract><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>transperineal prostate biopsy</kwd><kwd>infectious complication</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>трансперинеальная биопсия предстательной железы</kwd><kwd>инфекционное осложнение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Mottet N., Bellmunt J., Briers E. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer, 2020. Pp. 31-45. Available at: https://uroweb.org/wp-content/uploads/Mottet-N-et-al.-Eur-Urol-2021-792243.-EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020-Update.-Part-1.pdf.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Borghesi M., Ahmed H., Nam R. et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 2017;71(3):353-65. DOI: 10.1016/j.eururo.2016.08.004.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Wenzel M., Theissen L., Preisser F. et al. Complication rates after TRUS guided transrectal systematic and MRI-targeted prostate biopsies in a high-risk region for antibiotic resistances. Front Surg 2020;7:7. DOI: 10.3389/fsurg.2020.00007.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Keln A.A., Zyryanov A.V., Izmailov A.A. et al. Comparative analysis of adverse events using different methods of prostate biopsy. Onkourologiya = Cancer Urology 2019;15(1):66-74. (In Russ.). DOI: 10.17650/1726-9776-2019-15-1-66-74</mixed-citation><mixed-citation xml:lang="ru">Кельн А.А., Зырянов А.В., Измайлов А.А. и др. Сравнительный анализ нежелательных явлений при исполь-зовании различных методик биопсии предстательной железы. Онкоурология 2019;15(1):66-74. DOI: 10.17650/1726-9776-2019-15-1-66-74</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Loeb S., van den Heuvel S., Zhu X. et al. Infectious complications and hospital admissions after prostate biopsy in a european randomized trial. 2012;61(6):1110-4. DOI: 10.1016/j.eururo.2011.12.058.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Franck B., Sandra M., Philippe B. et al. Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol 2015;193(1):145-50. DOI: 10.1016/j.juro.2014.07.086.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lundstrom K.J., Drevin L., Carlsson S. et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol 2014;192(4):1116-22. DOI: 10.1016/j.juro.2014.04.098.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Roberts M.J., Bennett H.Y., Harris P.N. et al. Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches. Urology 2017;104:11-21. DOI: 10.1016/j.urology.2016.12.011.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Nam R.K., Saskin R., Lee Y. et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2013;189(1):S12-8. DOI: 10.1016/j.juro.2012.11.015.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wei T., Lin T., Chang Y. et al. Transrectal ultrasound-guided prostate biopsy in Taiwan: a nationwide database study. J Chinese Med Assoc 2015;78(11):662-5. DOI: 10.1016/j.jcma.2015.04.011.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Johansen T., Zahl P.H., Baco E. et al. Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry. World J Urol 2020;38(1):17-26. DOI: 10.1007/s00345-019-02837-0.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Liss M.A., Chang A., Santos R. et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 2011;185(4):1283-8. DOI: 10.1016/j.juro.2010.11.088.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chung H.S., Hwang E.C., Yu H.S. et al. Prevalence of fluoroquinolone-resistant rectal flora in patients undergoing transrectal ultrasound-guided prostate needle biopsy: a prospective multicenter study. Int J Urol 2018;25(3):278-83. DOI: 10.1111/iju.13511.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Knaapila J., Gunell M., Syvanen K. et al. Prevalence of complications leading health care contact after transrectal prostate biopsies: a prospective, controlled, multicenter study based on a selected study cohort. Eur Urol Focus 2019;5(3):443-8. DOI: 10.1016/j.euf.2017.12.001.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>The Center for Disease Dynamics, Economics &amp; Policy. Resistance Map: Russia. 2020.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Grabe M., Bartoletti R., Bjerklund-Johansen T.E. et al. Guidelines on Urological Infections. Eur Assoc Urol, 2015. Pp. 33-40. Available at: https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Quinolone- and fluoroquinolonecontaining medicinal products. Vol. 31, EMA European Medicines Agency, 2019. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products#all-documents-section %0Ahttps://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquino-lone-containing-medicinal-products.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Guo L.H., Wu R., Xu H.X. et al. Comparison between ultrasound guided transperineal and transrectal prostate biopsy: a prospective, randomized, and controlled trial. Sci Rep 2015;5:16089. DOI: 10.1038/srep16089.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Grummet J.P., Weerakoon M., Huang S. et al. Sepsis and “superbugs”: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int 2014;114(3):384-8. DOI: 10.1111/bju.12536.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Vyas L., Acher P., Kinsella J. et al. Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases. BJU Int 2014;114(1):32-7. DOI: 10.1111/bju.12282.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Wadhwa K., Carmona-Echeveria L., Kuru T. et al. Transperineal prostate biopsies for diagnosis of prostate cancer are well tolerated: a prospective study using patient - reported outcome measures. Asian J Androl 2017;19(1):62-6. DOI: 10.4103/1008-682x.173453.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Pepdjonovic L., Hee G., Huang S. et al. Zero hospital admissions for infection after 577 transperineal prostate biopsies using single - dose cephazolin prophylaxis. World J Urol 2017;35(8):1199-203. DOI: 10.1007/s00345-016-1985-1.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Gorin M.A., Meyer A.R., Zimmerman M. et al. Transperineal prostate biopsy with cognitive magnetic resonance imaging/biplanar ultrasound fusion: description of technique and early results. World J Urol 020;38(8):1943-9. DOI: 10.1007/s00345-019-02992-4.</mixed-citation></ref></ref-list></back></article>
